Characterization of Diarrhea Adverse Events with Nerandomilast in Patients with Autoimmune Interstitial Lung Disease and Progressive Pulmonary Fibrosis in the FIBRONEER-ILD Trial [WITHDRAWN] (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1400; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; P4 | "Adults with moderate to severe RA with a diagnosis consistent with 2010 ACR/EULAR classification criteria and ≥1 predefined VTE risk factor (prior VTE, age ≥60 years, BMI ≥30 kg/m2, or age 50-< 60 with BMI 25-< 30 kg/m2) were randomized 1:1:1 to baricitinib 2 or 4mg QD, or TNFi (adalimumab or etanercept). In active RA patients with increased VTE risk, noninferiority of baricitinib vs TNFi for VTE was not demonstrated, although the CI crossed 1. MACE and mortality were similar between groups. SIs were more frequent with baricitinib vs TNFi, largely driven by COVID-19 events."
Adverse events • Clinical • Genetic Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Pneumonia • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Skin Cancer • Solid Tumor • CRP
|